Guía de Práctica Clínica sobre Cuidados Paliativos - Cedepap TV

242. Cancer care Ontario Practice Guidelines Initiative. Use of 5-HT 3receptor antagonists in patientsreceiving moderately or highly emetogenic chemotherapy. Disponible en: www cancercareon ca/ [accedido en: septiembre 2007]243. Critchley P, Plach N, Grantham M, Marshall D, Taniguchi A, Latimer E, et al. Efficacy ofhaloperidol in the treatment of nausea and vomiting in the palliative patient: A systematicreview [3]. Journal of Pain & Symptom Management. 2001;22(2):631-4.244. Aapro MS, Molassiotis A, Olver I. Anticipatory nausea and vomiting. Support Care Cancer.2005;13(2):117-21.245. Ahmedzai SH, Boland j. Constipation in people prescribed opioids. In: BMJ Publishing Group,editor. Clinical Evidence. London: 2007. p. 2407.246. Miles CL, Fellowes D, Goodman ML, Wilkinson S. Laxatives for the management of constipationin palliative care patients. Cochrane Database Syst Rev. 2006;(4):CD003448.247. Sykes N. Constipation and diarrhoea. In: Doyle D, Hanks G, Chreney N, Calman K, editors.Oxford Textbook of Palliative Medicine. Third ed. Oxford: Oxford University Press; 2004. p.483-96.248. Benson AB, III, Ajani JA, Catalano RB, Engelking C, Kornblau SM, Martenson JA, Jr., etal. Recommended guidelines for the treatment of cancer treatment-induced diarrhea. J ClinOncol. 2004;22(14):2918-26.249. Cascinu S, Bichisao E, Amadori D, Silingardi V, Giordani P, Sansoni E, et al. High-dose loperamidein the treatment of 5-fluorouracil-induced diarrhea in colorectal cancer patients.Supportive care in cancer : official journal of the Multinational Association of SupportiveCare in Cancer. 2000;8:65-7.250. Geller RB, Gilmore CE, Dix SP, Lin LS, Topping DL, Davidson TG, et al. Randomized trial ofloperamide versus dose escalation of octreotide acetate for chemotherapy-induced diarrhea in bonemarrow transplant and leukemia patients. American journal of hematology. 1995;50:167-72.251. Pezzella G, Pisconti S. Octreotide versus loperamide in controlling chemotherapy-induceddiarrhoea. Giornale Italiano di Oncologia. 1994;14:79-82.252. Cascinu S, Fedeli A, Fedeli SL, Catalano G. Octreotide versus loperamide in the treatmentof fluorouracil-induced diarrhea: a randomized trial. Journal of clinical oncology : officialjournal of the American Society of Clinical Oncology. 1993;11:148-51.253. Sherman DM, Mangini L, Poirier P, Kadish SP. Double-blind comparison of loperamide andplacebo in the treatment of radiation-induced diarrhea. ADV THER. 1989;6:103-11.254. Szilagyi A, Shrier I. Systematic review: the use of somatostatin or octreotide in refractorydiarrhoea. Aliment Pharmacol Ther. 2001;15(12):1889-97.255. Ripamonti C, Mercadante S. Pathophysiology and management of malignant bowel obstruction.In: Doyle D, Hanks G, Chreney N, Calman K, editors. Third ed. Oxford: Oxford UniversityPress; 2004. p. 496-507.256. Ripamonti C, Twycross R, Baines M, Bozzetti F, Capri S, De Conno F, et al. Clinical-practicerecommendations for the management of bowel obstruction in patients with end-stagecancer. Supportive Care in Cancer. 2001;9(4):223-33.257. Watt AMB, Faragher IGF, Griffin TTP, Rieger NAM, Maddern GJP. Self-expanding MetallicStents for Relieving Malignant Colorectal Obstruction: A Systematic Review. [Review].Annals of Surgery. 2007;246(1):24-30.GUÍA DE PRÁCTICA CLÍNICA SOBRE CUIDADOS PALIATIVOS 301